A new device that delivers 15 minutes of transnasal evaporative cooling produced effective pain relief for people with acute episodic migraine, in a small, randomized trial.
Dr Nathaniel Schuster from UC San Diego and colleagues tested a cannabis product with 6% THC based on prior studies showing efficacy of that concentration for other pain conditions.
Intranasal ketamine may offer new hope for people with chronic, refractory migraines where other treatments fail. However, concerns about the addictive nature of the drug may limit its use.